NUCLEAR MEDICINE--CORE

核医学核心将为以下方面提供关键支持： 淋巴瘤治疗的三个临床项目的工作 用I-131标记的单克隆抗体检测白血病。 的 具体目的是1）制备适合的I-131标记的抗体， 用于患者的初始诊断和剂量测定研究 进入研究方案，2）通过串行伽马采集数据 摄像成像、全身计数、血液、尿液和 用于估计内辐射的组织样本 吸收剂量，3）得出有意义的内部估计值 个体患者的辐射剂量测定和4）准备和 给予高剂量（300 mCi或更高）I-131标记抗体 准备治疗。 这些研究将在蛋白质标记实验室进行， 核医学部核医学诊所和 大学医院肿瘤科病房 低剂量和高剂量 I-131标记最初将通过亲电方法进行 尽管当开发出替代方法时可以使用它们 通过核工业部的其他研究项目， 药

The Nuclear Medicine Core will provide critical support for the work of the three clinical projects in the treatment of lymphoma and leukemia with I-131 labeled monoclonal antibodies. The specific aims are 1) to prepare I-131 labeled antibodies suitable for the initial diagnostic and dosimetric studies of patients entering the study protocols, 2) to collect data by serial gamma camera imaging, whole body counting, analysis of blood, urine and tissue samples to be used for estimations of internal radiation absorbed dose, 3) to derive meaningful estimates of internal radiation dosimetry for individual patients and 4) to prepare and administer high dose (300 or more mCi) I-131 labeled antibody preparations for therapy. These studies will be done in the protein labeling laboratories, Nuclear Medicine Clinics of the Division of Nuclear Medicine and the Oncology Ward of the University Hospital. Low and high dose I-131 labeling will be done initially by electrophilic methods though alternate methods may be used as they are developed through other research programs in the Division of Nuclear Medicine.